CX717 — Safety, Research, Risks & Legal Status

Not medical advice. CX717 is discussed here for informational and harm-reduction purposes only. We do not endorse use, and any dosing context is informational, not a protocol.

Also known as	Ampakine CX717; RespireRx CX717
Category	Research Chemical
Developer (current)	RespireRx Pharmaceuticals (original developer: Cortex Pharmaceuticals)
Chemical class	Low-impact ampakine; positive allosteric modulator of AMPA-type glutamate receptors
Pharmacokinetics	Half-life ~8-12 hours; Tmax ~3-5 hours; dose-proportional oral exposure; not significantly food-affected
Phase 2A ADHD result (2025)	Primary endpoint met on ADHD-RS at 800 mg BID vs. placebo in adult ADHD; published in European Journal of Pharmacology (PMID 40783159)
Key unresolved safety signal	Brain vacuolation in animal toxicology (2007, FDA concern); sponsor disputed as postmortem artifact; unresolved in published literature
Regulatory history	IND accepted 2005; Phase IIb denied by FDA 2007 (ADHD); active Phase 2A data 2025; no approved indication
US legal status	Not FDA-approved. CX717 is an investigational drug with no approved indication in the United States. It is not legally available for human use outside of authorized clinical trials. It is not classified as a controlled substance but is regulated as an unapproved new drug under 21 U.S.C. § 355. Sales or distribution outside of clinical research contexts would violate federal law. Not a dietary supplement.

What is CX717?

CX717 is an experimental low-impact ampakine - a positive allosteric modulator of AMPA-type glutamate receptors. It was originally developed by Cortex Pharmaceuticals and is currently under clinical development by RespireRx Pharmaceuticals. The compound is distinguished from earlier, high-impact ampakines by its comparatively minimal effect on AMPA receptor desensitization, a design choice intended to reduce the epileptogenic risk associated with the ampakine class. It is being investigated primarily for ADHD and opioid-induced respiratory depression, with early-phase human trial data available but no approved clinical use.

How it works

CX717 acts as a positive allosteric modulator at AMPA-type (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) glutamate receptors. By partially reducing receptor desensitization, it prolongs and enhances excitatory synaptic transmission mediated by AMPA receptors without directly activating them. This is the same broad mechanism shared by the ampakine class, but CX717 is categorized as a "low-impact" compound because it produces a weaker offset of desensitization compared to earlier high-impact ampakines such as CX546. The rationale is that excessive facilitation of AMPA receptor activity can lower seizure threshold; the low-impact designation is intended to retain cognitive and respiratory drive enhancement while staying below that risk threshold. Downstream, enhanced AMPA signaling is hypothesized to support synaptic plasticity, sustained attention, and respiratory rhythm generation in brainstem circuits.

Background & history

CX717 was discovered by Christopher Marrs and Gary Rogers and developed by Cortex Pharmaceuticals, Inc. (founded 1989, Irvine, CA), a company focused on the ampakine class throughout the 1990s and 2000s. In 2005, the U.S. Department of Defense funded primate studies demonstrating that CX717 could reverse cognitive deficits induced by sleep deprivation. That same year, the FDA accepted an Investigational New Drug (IND) application for Phase II evaluation in adult ADHD. A 2006 DARPA-funded study in healthy humans reported no significant cognitive improvement. In 2007, the FDA denied Cortex's Phase IIb application for ADHD, citing animal toxicology findings of brain vacuolation - a finding Cortex disputed as a postmortem tissue fixation artifact rather than a drug effect; the dispute was not definitively resolved. Cortex also observed poor oral bioavailability in the 800 mg formulation, prompting development of an intravenous route for the respiratory indication. Following corporate restructuring, RespireRx Pharmaceuticals acquired development rights. Between 2024 and 2026, RespireRx reactivated clinical programs: Phase 2A ADHD data published in 2025 reported the primary endpoint (ADHD-RS improvement at 800 mg BID) was met, and Phase IIa trials for opioid-induced respiratory depression achieved positive endpoints in European studies.

What the research says

Evidence base is early-phase clinical and preclinical. In animal models, particularly non-human primates, CX717 reversed sleep-deprivation-induced cognitive deficits (DoD-funded, 2005). In humans, over 220 healthy subjects and patients have been dosed across multiple trials. A Phase 2A trial in adult ADHD (published 2025, PubMed PMID 40783159) met its primary endpoint of improvement on the ADHD Rating Scale (ADHD-RS) at 800 mg BID versus placebo. Phase IIa trials for opioid-induced respiratory depression and central sleep apnea conducted in Europe reported positive endpoints. Pharmacokinetic and safety data in healthy young and elderly subjects were published in 2024 (PubMed PMID 39892449). All evidence should be characterized as early-phase: no Phase III data exist, no head-to-head comparisons with approved agents have been published, and regulatory approval has not been obtained for any indication. The 2007 brain vacuolation safety signal in animals remains unresolved in the literature, though human trials to date have not reproduced a corresponding finding.

Reported effects

Positive allosteric modulation of AMPA-type glutamate receptors (mechanism, not a claimed benefit)
Reversal of sleep-deprivation-induced cognitive deficits in non-human primate models (preclinical)
Improvement on ADHD Rating Scale (ADHD-RS) versus placebo in a Phase 2A adult ADHD trial (early human data, not an approved indication)
Attenuation of opioid-induced respiratory depression in Phase IIa trials (early human data, investigational)
Potential signal for improvement in central sleep apnea in European Phase IIa studies (preliminary)
No significant cardiovascular effects (heart rate, blood pressure) observed across tested dose ranges in published safety studies

Dosing & administration (informational)

Published clinical trials have used doses ranging from single oral doses up to 1600 mg and a twice-daily regimen of 800 mg BID in the Phase 2A ADHD study. An intravenous formulation has also been developed for the respiratory indication at separate dose ranges. These figures are reported from the literature for informational and research reference purposes only. They do not constitute a dosing protocol or clinical recommendation. CX717 is not approved for any indication, and no safe or effective dose has been established outside of controlled trial settings. Consult a licensed clinician and refer to active trial protocols for any clinical questions.

This is general research/context information, not medical advice or a recommended protocol.

Safety & side effects

FDA denied Phase IIb ADHD application in 2007 citing brain vacuolation in animal toxicology; sponsor disputed finding as postmortem fixation artifact; this question is not definitively resolved in public literature
Most common adverse events in human trials: headache, dizziness, nausea, and mild sleep disturbance
No serious adverse events reported across 220+ subjects dosed in published trials, though this sample size is insufficient to characterize rare events
No significant cardiovascular effects (heart rate, blood pressure) observed at doses up to 800 mg BID and single doses up to 1600 mg
Theoretical class-level risk: high-impact ampakines lower seizure threshold; CX717 is low-impact by design to mitigate this, but long-term epileptogenicity data in humans do not exist
Pharmacokinetics: half-life approximately 8-12 hours, Tmax 3-5 hours, exposure dose-proportional, not significantly affected by food
Not approved for human use; obtaining or using outside a clinical trial is unsupported by any regulatory authorization and carries unknown risks

Drug & supplement interactions

N
o
f
o
r
m
a
l
d
r
u
g
-
d
r
u
g
i
n
t
e
r
a
c
t
i
o
n
s
t
u
d
i
e
s
a
r
e
d
e
s
c
r
i
b
e
d
i
n
t
h
e
a
v
a
i
l
a
b
l
e
p
u
b
l
i
s
h
e
d
l
i
t
e
r
a
t
u
r
e
.
A
s
a
g
l
u
t
a
m
a
t
e
r
g
i
c
a
g
e
n
t
,
C
X
7
1
7
c
o
u
l
d
t
h
e
o
r
e
t
i
c
a
l
l
y
i
n
t
e
r
a
c
t
w
i
t
h
o
t
h
e
r
c
o
m
p
o
u
n
d
s
a
f
f
e
c
t
i
n
g
e
x
c
i
t
a
t
o
r
y
n
e
u
r
o
t
r
a
n
s
m
i
s
s
i
o
n
.
I
t
s
i
n
v
e
s
t
i
g
a
t
i
o
n
i
n
t
h
e
c
o
n
t
e
x
t
o
f
o
p
i
o
i
d
-
i
n
d
u
c
e
d
r
e
s
p
i
r
a
t
o
r
y
d
e
p
r
e
s
s
i
o
n
i
m
p
l
i
e
s
s
o
m
e
s
t
u
d
y
i
n
t
h
e
p
r
e
s
e
n
c
e
o
f
o
p
i
o
i
d
s
;
t
r
i
a
l
d
a
t
a
s
u
g
g
e
s
t
i
t
c
a
n
p
a
r
t
i
a
l
l
y
a
n
t
a
g
o
n
i
z
e
o
p
i
o
i
d
-
i
n
d
u
c
e
d
r
e
s
p
i
r
a
t
o
r
y
s
u
p
p
r
e
s
s
i
o
n
,
b
u
t
t
h
e
p
h
a
r
m
a
c
o
d
y
n
a
m
i
c
i
n
t
e
r
a
c
t
i
o
n
p
r
o
f
i
l
e
w
i
t
h
C
N
S
d
e
p
r
e
s
s
a
n
t
s
,
s
t
i
m
u
l
a
n
t
s
,
o
r
o
t
h
e
r
p
s
y
c
h
o
a
c
t
i
v
e
d
r
u
g
s
h
a
s
n
o
t
b
e
e
n
s
y
s
t
e
m
a
t
i
c
a
l
l
y
c
h
a
r
a
c
t
e
r
i
z
e
d
i
n
p
u
b
l
i
s
h
e
d
h
u
m
a
n
d
a
t
a
.
N
o
i
n
t
e
r
a
c
t
i
o
n
g
u
i
d
a
n
c
e
i
s
a
v
a
i
l
a
b
l
e
f
o
r
u
n
s
u
p
e
r
v
i
s
e
d
u
s
e
.

Who should avoid it

Use outside of authorized clinical trial settings - no approved indication exists
Combination with proconvulsant agents or other AMPA receptor modulators given theoretical class-level epileptogenic concerns
Self-administration based on preclinical or early-phase data - human safety and efficacy profile is not established at scale
Use by individuals with personal or family history of seizure disorders, absent specialist evaluation
Reliance on this compound as a substitute for evaluated ADHD pharmacotherapy - approved and evidence-supported options exist

How it is commonly combined

No stacking protocols or combination regimens are supported by clinical evidence. CX717 has not been studied in combination with stimulants, nootropics, or other AMPA modulators in human trials. Combining glutamatergic modulators carries theoretical risks of excessive excitatory signaling. No combination use can be recommended on the basis of available evidence.

Legal & regulatory. Not FDA-approved. CX717 is an investigational drug with no approved indication in the United States. It is not legally available for human use outside of authorized clinical trials. It is not classified as a controlled substance but is regulated as an unapproved new drug under 21 U.S.C. § 355. Sales or distribution outside of clinical research contexts would violate federal law. Not a dietary supplement.

Quality & harm reduction

Safer, legal alternative we recommend

Sleepio Formula. For the same sleep goal, our Sleep Formula is a legal, non-prescription option you can buy now.

See our recommended pick

Find CX717 →

Know your numbers before you research

Order your own bloodwork online — hormone, metabolic and inflammation panels, no doctor visit needed. Know your baselines before and during any protocol. Independent bloodwork is the cheapest insurance there is.

Get tested with Ulta Lab Tests →

Frequently asked questions

What makes CX717 a 'low-impact' ampakine?

The distinction refers to the degree of offset of AMPA receptor desensitization. High-impact ampakines such as CX546 strongly slow receptor desensitization, which enhances excitatory signaling robustly but also lowers seizure threshold. CX717 produces a weaker, more partial effect on desensitization, which was intended to retain therapeutic benefit while staying below the epileptogenic range observed with first-generation compounds.

Why did the FDA deny Phase IIb trials for ADHD in 2007?

The FDA cited findings of brain vacuolation - small fluid-filled spaces in brain tissue - observed in animal toxicology studies. Cortex Pharmaceuticals disputed this interpretation, arguing the finding was an artifact of how the tissue was fixed after the animal was sacrificed (a postmortem processing artifact) rather than a drug-induced lesion. The dispute was not definitively resolved in public records, but subsequent human trials proceeding under IND have not reported a corresponding neurological finding.

Has CX717 shown benefit in human ADHD trials?

A Phase 2A trial published in 2025 (PMID 40783159) reported that 800 mg BID met the primary endpoint of improvement on the ADHD Rating Scale (ADHD-RS) versus placebo in adults. This is early-phase data from a single trial. No Phase III trials have been completed, no regulatory approval has been granted, and no head-to-head comparison with approved ADHD medications has been published.

What is the status of the respiratory depression indication?

Phase IIa trials for opioid-induced respiratory depression and central sleep apnea - conducted largely in Europe - have reported positive endpoints according to available sources. These remain investigational findings. The intravenous formulation was developed for this indication because the oral formulation showed poor blood-brain barrier penetration at the doses used. No approval has been obtained for this indication either.

Can I obtain or try CX717?

No legitimate non-trial source exists. CX717 is a proprietary investigational compound. It is not a dietary supplement and is not sold as a research chemical through legitimate channels. Any material purporting to be CX717 outside of a clinical trial cannot be verified for identity or purity. Participation in an authorized clinical trial registered on ClinicalTrials.gov would be the only appropriate route to access the compound under medical supervision.

What is the recommended dose of CX717?

No dose has been approved or established for any clinical indication. Published trials report specific regimens (e.g., 800 mg BID orally in the ADHD Phase 2A trial) as experimental protocols, not as dosing recommendations. Dosing in any therapeutic context should be determined by a licensed clinician within an authorized clinical setting. This reference does not provide dosing guidance.

References & further reading

PubMed: CX717 ADHD phase 2A ampakine RespireRx clinical trial 2025 (PMID 40783159)
PubMed: CX717 safety pharmacokinetics healthy subjects elderly young 2024 (PMID 39892449)
PubMed: low-impact ampakine opioid-induced respiratory depression phase IIa
ClinicalTrials.gov: search 'CX717' for active and completed registrations under RespireRx Pharmaceuticals
PubMed: ampakine AMPA receptor positive allosteric modulator sleep deprivation primate cognition Cortex Pharmaceuticals 2005